RNAZ Stock Overview
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TransCode Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$356.00 |
| 52 Week Low | US$0.47 |
| Beta | -0.34 |
| 1 Month Change | -27.25% |
| 3 Month Change | -38.41% |
| 1 Year Change | -99.82% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
TransCode Therapeutics reports Q2 results
Aug 15TransCode files U.S. patent application for radiotherapy based cancer treatment
Jul 11We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely
Apr 01
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation
Dec 15Shareholder Returns
| RNAZ | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.5% | -4.2% | -3.7% |
| 1Y | -99.8% | -2.0% | 20.5% |
Return vs Industry: RNAZ underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: RNAZ underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| RNAZ volatility | |
|---|---|
| RNAZ Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RNAZ's share price has been volatile over the past 3 months.
Volatility Over Time: RNAZ's weekly volatility has decreased from 45% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 10 | Tom Fitzgerald | www.transcodetherapeutics.com |
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
TransCode Therapeutics, Inc. Fundamentals Summary
| RNAZ fundamental statistics | |
|---|---|
| Market cap | US$2.92m |
| Earnings (TTM) | -US$18.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs RNAZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.55m |
| Earnings | -US$18.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RNAZ perform over the long term?
See historical performance and comparison